Trends in Prevalence of Dyslipidaemias and the Risk of Mortality in Lithuanian Urban Population Aged 45–64 in Relation to the Presence of the Dyslipidaemias and the Other Cardiovascular Risk Factors
The aim of this study was to provide reliable information on dyslipidaemias, to estimate the trend of the prevalence of dyslipidaemias and other selected cardiovascular disease (CVD) risk factors at population level, and to evaluate the risk of all-cause and CVD mortality in relation to presence of mixed dyslipidaemias and other CVD risk factors. Methods Data from the five surveys (1983–2008) are presented. A random sample of 9,209 subjects aged 45–64 was selected for statistical analysis. During follow-up there were 1653 death cases from any cause, 864 deaths from CVD. Estimates of hazard ratios (HR) and 95% confidence intervals (CI) were based on the multivariate Cox proportional hazards regression for all-cause mortality and CVD mortality. Results During 25 year period the prevalence of normal total cholesterol level (<5.2 mmol/L) significantly increased only in women; triglycerides and high density lipoprotein (HDL) cholesterol did not change in men and women. Findings in our longitudinal study showed that in men and women mixed dyslipidaemias (HDL cholesterol <1.03 mmol/L plus triglycerides ≥1.70 mmol/L) significantly increased the risk for all-cause and CVD mortality (respectively in men HR = 1.30; HR = 1.15, in women HR = 1.83; HR = 2.13). These mixed dyslipidaemia combinations combination with the other risk factors such as arterial hypertension, high fasting glucose level increased all-cause and CVD mortality risk in men and women; while, these mixed dyslipidaemias plus smoking increased all-cause and CVD mortality risk only in men compared to never smokers without these dyslipidaemias (respectively HR = 1.89; HR = 1.92); and these dyslipidaemias plus obesity increased all-cause and CVD mortality risk in women (respectively HR = 2.25; HR = 2.39) and CVD mortality risk in men (HR = 1.72), as compared to responders without obesity and these dyslipidaemias. Conclusion Mixed dyslipidaemias (reduced HDL cholesterol plus elevated triglycerides) significantly increased the risk for all-cause and CVD mortality in this Lithuanian population aged 45–64 years.
References
[1]
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis 22: 1e68.
[2]
World Health Organization (2009) Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva: World Health Organization Press.
[3]
Health in the Baltic countries 2011 (2013). 20th edition. Health Information Centre, Institute of Hygiene; Vilnius, Available: http://sic.hi.lt
[4]
European Health for All Database (HFA-DB). Available: http://www.euro.who.int/hfadb Accessed 12 May 2013
[5]
Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110: 227–239. doi: 10.1161/01.cir.0000133317.49796.0e
[6]
Laforest L, Ambegaonkar BM, Souchet T, Sazonov V, Van Ganse E (2012) Mixed dyslipidemias in primary care patients in France. Vasc Health Risk Manag 8: 247–254. doi: 10.2147/vhrm.s27668
Assmann G, Schulte H (1992) Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 70: 733–737. doi: 10.1016/0002-9149(92)90550-i
[9]
Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, et al. (2007) HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357: 1301–1310. doi: 10.1056/nejmoa064278
[10]
Morrison A, Hokanson JE (2009) The independent relationship between triglycerides and coronary heart disease. Vasc Health Risk Manag 5: 89–95. doi: 10.2147/vhrm.s4311
[11]
Paolillo S, Della Ratta GL, Vitagliano A, Cirillo A, et al. (2013) New perspectives in cardiovascular risk reduction: focus on HDL. Monaldi Arch Chest Dis 80: 27–30.
[12]
Tóth PP, Potter D, Ming EE (2012) Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003–2006. J Clin Lipidol 6: 325–330. doi: 10.1016/j.jacl.2012.05.002
[13]
Wietlisbach V, Marques-Vidal P, Kuulasmaa K, Karvanen J, Paccaud F, et al. (2013) The relation of body mass index and abdominal adiposity with dyslipidemia in 27 general populations of the WHO MONICA Project. Nutr Metab Cardiovasc Dis 23: 432–442. doi: 10.1016/j.numecd.2011.09.002
[14]
Cullen P, Schulte H, Assmann G (1998) Smoking, lipoproteins and coronary heart disease risk. Data from the Munster Heart Study (PROCAM). Eur Heart J 19: 1632–1641. doi: 10.1053/euhj.1998.1086
[15]
Klop B, Elte JW, Cabezas MC (2013) Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 5: 1218–1240. doi: 10.3390/nu5041218
[16]
West KM, Ahuja MM, Bennett PH, Czyzyk A, De Acosta OM, et al. (1983) The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 6: 361–369. doi: 10.2337/diacare.6.4.361
[17]
Peasey A, Bobak M, Kubinova R, Malyutina S, Pajak A, et al. (2006) Determinants of cardiovascular disease and other non-communicable diseases in Central and Eastern Europe: Rationale and design of the HAPIEE study. BMC Public Health 6: 255 doi:10.1186/1471-2458-6-255.
[18]
Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106: 3143–3342. doi: 10.1001/jama.285.19.2486
[19]
Norkus A, Ostrauskas R, Sulcaite R, Baranauskiene E, Baliutaviciene D (2000) Classification and diagnosis of diabetes mellitus (methodology recommendations). Lith Endocrinol 3: 234–241.
[20]
The World Health Organization Database (2012) Available: http://www.who.int/gho/countries/en. Accessed 21 August 2012.
[21]
The World Health Organization: Multinational Monitoring of trends and determinants in Cardiovascular disease (MONICA) project monograph database. Available: http://www.ktl.fi/monica/public/monograp？h.html. Accessed 21 August 2012.
[22]
Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, et al. (2011) National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3？0 million participants. Lancet 377: 578–586. doi: 10.1016/s0140-6736(10)62038-7
[23]
Carroll MD, Kit BK, Lacher DA, Shero ST, Mussolino ME (2012) Trends in lipids and lipoproteins in US adults, 1988–2010. JAMA 308: 1545–1554. doi: 10.1001/jama.2012.13260
[24]
Johansson I, Nilsson LM, Stegmayr B, Boman K, Hallmans G, et al. (2012) Associations among 25-year trends in diet, cholesterol and BMI from 140,000 observations in men and women in Northern Sweden. Nutr J 11: 40 doi: 10.1186/1475-2891-11-40.
[25]
Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, et al. (2012) Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA 307: 1273–1283. doi: 10.1001/jama.2012.339
[26]
Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M (2008) Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocr 34: 36–51. doi: 10.1007/s12020-008-9100-z
[27]
Fuentes R, Uusitalo T, Puska P, Tuomilehto J, Nissinen A (2003) Blood cholesterol level and prevalence of hypercholesterolaemia in developing countries: a review of population-based studies carried out from 1979 to 2002. Eur J Cardiovasc Prev Rehabil 10: 411–419. doi: 10.1097/01.hjr.0000085247.65733.4f
[28]
Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302: 1993e2000.
[29]
Barter P (2011) HDL-C: Role as a risk modifier. Atherosclerosis (Supplements 12) 3: 267–270. doi: 10.1016/s1567-5688(11)70885-6
[30]
The DECODE Study Group (2006) Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 49: 2837–2846. doi: 10.1007/s00125-006-0438-6
[31]
Liu J, Zeng FF, Liu ZM, Zhang CX, Ling WH, et al. (2013) Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis 12: 159. doi: 10.1186/1476-511x-12-159
[32]
Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, et al. (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370: 1829–1839. doi: 10.1016/s0140-6736(07)61778-4
[33]
Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report (2002). Circulation 106: , 3143–3421.
[34]
Luksiene D, Baceviciene M, Jureniene K, Bernotiene G, Reklaitiene R, et al. (2012) All-cause and cardiovascular mortality risk estimation using different definitions of metabolic syndrome in Lithuanian urban population. Prev Med 55: 299–304. doi: 10.1016/j.ypmed.2012.08.002
[35]
Garrison RJ, Kannel WB, Feinleib M, Castelli WP, McNamara PM, et al. (1978) Cigarette smoking and HDL cholesterol: the Framingham offspring study. Atherosclerosis 30: 17–25. doi: 10.1016/0021-9150(78)90149-1
[36]
Nakamura K, Nakagawa H, Sakurai M, Murakami Y, Irie F, et al. (2012) Influence of smoking combined with another risk factor on the risk of mortality from coronary heart disease and stroke: pooled analysis of 10 Japanese cohort studies. Cerebrovasc Dis 33: 480–491. doi: 10.1159/000336764
[37]
Rao Ch S, Subash Y E (2013) The effect of chronic tobacco smoking and chewing on the lipid profile. J Clin Diagn Res 7: 31–34. doi: 10.7860/jcdr/2012/5086.2663
[38]
Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, et al. (2007) Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 116: 151–157. doi: 10.1161/circulationaha.106.685628
[39]
Zhang L, Qiao Q, Tuomilehto J, Hammar N, Ruotolo G, et al. (2009) The impact of dyslipidaemia on cardiovascular mortality in individuals without a prior history of diabetes in the DECODE Study. Atherosclerosis 206: 298–302. doi: 10.1016/j.atherosclerosis.2008.12.043
[40]
Clarke R, Emberson J, Fletcher A, Breeze E, Marmot M, et al. (2009) Life expectancy in relation to cardiovascular risk factors: 38 year follow-up of 19,000 men in the Whitehall study. BMJ 339: b3513. doi: 10.1136/bmj.b3513
[41]
Smalinskiene A, Petkeviciene J, Luksiene D, Jureniene K, Klumbiene J, et al. (2013) Association between APOE, SCARB1, PPARα polymorphisms and serum lipids in a population of Lithuanian adults. Lipids Health Dis 12: 120 doi: 10.1186/1476-511X-12-120.
[42]
Kriaucionien？ V, Klumbiene J, Petkeviciene J, Sakyte E (2012) Time trends in social differences in nutrition habits of a Lithuanian population: 1994–2010. BMC Public Health 12: 218. doi: 10.1186/1471-2458-12-218
[43]
Lowe G, Woodward M, Hillis G, Rumley A, Li Q, et al. (2014) Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes 63: 1115–1123. doi: 10.2337/db12-1625
[44]
Veeranna V, Zalawadiya SK, Panaich S, Patel KV, Afonso L (2013) Comparative analysis of red cell distribution width and high sensitivity C-reactive protein for coronary heart disease mortality prediction in multi-ethnic population: findings from the 1999–2004 NHANES. Int J Cardiol 168: 5156–5161. doi: 10.1016/j.ijcard.2013.07.109
[45]
Rohde LE, Hennekens CH, Ridker PM (1999) Survey of Creactive protein and cardiovascular risk factors in apparently health men. Am J Cardiol 84: 1018–1022. doi: 10.1016/s0002-9149(99)00491-9
[46]
Barinas-Mitchell E, Cushman M, Meilahn EN, Tracy RP, Kuller LH (2001) Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. Am J Epidemiol 153: 1094–1101. doi: 10.1093/aje/153.11.1094
[47]
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for health care professionals from the Center for Disease Control and Prevention and the American Heart Association. Circulation 107: 499–511. doi: 10.1161/01.cir.0000052939.59093.45
[48]
Koenig W, Khuseyinova N, Baumert J, Meisinger C (2008) Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984–1998. Clin Chem 54: 335–342. doi: 10.1373/clinchem.2007.100271
[49]
Choi J, Joseph L, Pilote L (2013) Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev 14: 232–244. doi: 10.1111/obr.12003
[50]
Tsai HJ, Tsai ACH (2008) The association of plasma C-reactive protein levels with anthropometric and lipid parameters in elderly Taiwanese Asia. Pac J Clin Nutr 17: 651–656.
[51]
Kawamoto R, Kusunoki T, Abe M, Kohara K, Miki T (2013) An association between body mass index and high-sensitivity C-reactive protein concentrations is influenced by age in community-dwelling persons. Ann Clin Biochem 50: 457–464. doi: 10.1177/0004563212473445
[52]
Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF (2007) Systemic effects of smoking. Chest 131: 1557–1566. doi: 10.1378/chest.06-2179
[53]
Bazzano LA1, He J, Muntner P, Vupputuri S, Whelton PK (2003) Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 138: 891–897. doi: 10.1016/j.accreview.2003.08.037
[54]
Hamer M, Chida Y, Stamatakis E (2010) Association of very highly elevated C-reactive protein concentration with cardiovascular events and all-cause mortality. Clin Chem 56: 132–135. doi: 10.1373/clinchem.2009.130740
[55]
Herder C, Baumert J, Zierer A, Roden M, Meisinger C, et al. (2011) Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study. PLoS One 6: e19852 doi: 10.1371/journal.pone.0019852.
[56]
Gomes MS, Blattner TC, Sant'Ana Filho M, Grecca FS, Hugo FN, et al. (2013) Can apical periodontitis modify systemic levels of inflammatory markers? A systematic review and meta-analysis. J Endod 39: 1205–1217. doi: 10.1016/j.joen.2013.06.014
[57]
Padilha DM, Hilgert JB, Hugo FN, Bós AJ, Ferrucci L (2008) Number of teeth and mortality risk in the Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci 63: 739–744. doi: 10.1093/gerona/63.7.739
[58]
Sidaravicius B, Aleksejuniene J, Eriksen HM (1999) Endodontic treatment and prevalence of apical periodontitis in an adult population of Vilnius, Lithuania. Endod Dent Traumatol 15: 210–215. doi: 10.1111/j.1600-9657.1999.tb00776.x
